NLRP3 and COVID-19: Here, we have shown both in vitro and using a cohort of COVID-19 hospitalized patients with or without VitD3 treatment, that VitD3 exhibits an anti-inflammatory activity by targeting the NLRP3 inflammasome pathway at both transcriptional and translational levels.